MARKET

APRI

APRI

APRINOIA Therapeutics Inc.
NASDAQ
--
0.00
0.00%
Closed
OPEN
--
PREV CLOSE
--
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
--
52 WEEK LOW
--
MARKET CAP
--
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
1D
No Data
About APRI
APRINOIA Therapeutics Inc. is a clinical-stage biotechnology company engaged in protecting patients’ brain health and changing clinical outcomes for a range of neurodegenerative diseases by developing selective diagnostic tools and therapeutics. It is developing, APN-1607, as a positron emission tomography (PET) imaging tracer for the detection of 3R and 4R tau aggregates, which contribute to the pathogenesis of various tauopathies, including PSP, a rare neurodegenerative disease. It is also engaged in developing APN-1607 in progressive supranuclear palsy (PSP) and Alzheimer’s disease (AD) globally, independently or in collaboration with its partner. Its lead therapeutic product candidate, APNmAb005, is a humanized anti-tau antibody designed for the treatment of AD, non-AD primary tauopathies, including rare neurodegenerative disorders. Its PROTAC degrader offers a platform for the targeted degradation of toxic proteins that are causative in several neurodegenerative disorders.

Webull offers APRINOIA Therapeutics Inc. stock information, including NASDAQ: APRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APRI stock methods without spending real money on the virtual paper trading platform.